[Interim results of the combination of M2 polychemotherapy with calcitonin and synthetic anabolic agents in the treatment of plasmacytoma].
D000368:Aged; D045930:Anabolic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002116:Calcitonin / Q000008:administration & dosage / Q000627:therapeutic use*; D002330:Carmustine / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D013196:Dihydrotestosterone / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000032:analysis; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D010954:Plasmacytoma / Q000188:drug therapy* / Q000276:immunology; D011239:Prednisolone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D045930:Anabolic Agents; D000970:Antineoplastic Agents; D007147:Immunoglobulin Light Chains; D013196:Dihydrotestosterone; D014750:Vincristine; D003520:Cyclophosphamide; D002116:Calcitonin; D011239:Prednisolone; D008558:Melphalan; D002330:Carmustine
Risultati a medio termine dell'associazione di polichemioterapia M2 con calcitonina ed anabolizzanti di sintesi nella terapia del plasmocitoma.